BARCLAYS PLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 51 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2020$1,950,000
+1641.1%
2,629,000
+1805.1%
0.00%
Q1 2020$112,000
-86.1%
138,000
-85.3%
0.00%
-100.0%
Q3 2019$805,000
+509.8%
936,000
+532.4%
0.00%
Q2 2019$132,000
+2100.0%
148,000
+2014.3%
0.00%
Q4 2018$6,000
-97.3%
7,000
-97.6%
0.00%
Q3 2017$226,000293,0000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2019
NameSharesValueWeighting ↓
Worth Venture Partners, LLC 5,324,000$4,995,0003.78%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$53,020,0002.12%
DLD Asset Management, LP 32,500,000$30,048,0002.06%
Castle Creek Arbitrage, LLC 4,504,000$4,161,0001.43%
TENOR CAPITAL MANAGEMENT Co., L.P. 10,000,000$9,372,0000.62%
Graham Capital Management, L.P. 14,636,000$13,509,0000.60%
OAKTREE CAPITAL MANAGEMENT LP 64,452,000$59,704,0000.54%
Context Capital Management, LLC 1,000,000$926,0000.52%
ADVENT CAPITAL MANAGEMENT /DE/ 23,118,000$21,341,0000.52%
WOLVERINE ASSET MANAGEMENT LLC 18,583,000$17,322,0000.21%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders